In contrast, we demonstrate that concurrent treatment with STING agonist, anti-PD-1, olaparib and AZD1775 in AT3OVA tumours can overcome anti-PD-1 treatment resistance to result in durable tumour clearance. The gene discussed is STING1; the disease is neoplasm.